Avid Bioservices Inc (CDMO)

[cjgaddy]

Cedars-Sinai Researcher lists PPHM in her Disclosures in this Joint Mem.Sloan/Cedars-Sinai AACR’17 Abstract, where she's the Lead Author, along with co-authors Jedd Wolchok, Taha Merghoub, and several other Mem. Sloan researchers. So, 2 of Dr. Wolchok’s 5 AACR’17 abstracts are Joint PPHM+MemSloan, and a 3rd is Joint CedarsSinai+MemSloan whereby the Lead Author lists Peregrine in her disclosures. Maybe we need to add Cedars-Sinai to our collabs list along with Memorial Sloan Kettering, Duke, MDA, Rutgers, ImmunoVaccine, and UTSW.

AACR’17 4-4-17 #4705 “CTLA4 blockade with HER2-directed therapy yields clinical benefit in women undergoing Rad therapy (RT) for HER2+ breast cancer brain metastases”
Session: Immunomodulatory Agents & Therapeutics
Presenter/Authors:
Heather L. McArthur 1[Lead author, MD/MPH], Kathryn Beal 2, Darragh Halpenny 2, Micaela Henrich 2, Shanu Modi 2, Sujata Patil 2, Robert Young 2, Thomas Kaley 2, Taha Merghoub 2, Christopher Barker 2, Phillip Wong 2, Nicola Hamilton 2, Clifford Hudis 2, Jedd Wolchok 2, Larry Norton 2
1=Cedars-Sinai Medical Center, Los Angeles
2=Memorial Sloan Kettering Cancer Ctr., NYC
Disclosures:
Heather McArthur: Merck; OBI Pharma; Bristol Myers Squibb; Eli Lilly; MedImmune, AstraZeneca; Roche; Celgene; Calithera; Peregrine; Spectrum Pharm.
http://www.abstractsonline.com/pp8/#!/4292/presentation/6249
------
Breast Cancer Res. Foundation (BCRF) Bio: Heather L. McArthur, MD, MPH
Medical Director, Breast Oncology, Cedars-Sinai Medical Center, Los Angeles
https://www.bcrfcure.org/researchers/heather-l-mcarthur
.
.
NOTE: Mem. Sloan’s JEDD WOLCHOK is co-author of 5 AACR’17 Posters. 2 of the 5 are w/PPHM re: PS-Targeting. Only one other is with a biotech: Genocea Biosciences. The 4th is MSKCC ONLY, and the 5th is jointly w/Cedars-Sinai/LA. http://www.abstractsonline.com/pp8/#!/4292
PEREGRINE (Joint Mem.Sloan Kettering Wolchok Lab & PPHM):
1. 4-2-17 #574 “Phosphatidylserine Targeting Antibody in Combination with Tumor Radiation & Immune Checkpoint Blockade Promotes Anti-Tumor Activity in Mouse B16 Melanoma” <=same as SICT’16/11-14-16
2. 4-3-17 #1651 “Targeting Phosphatidylserine in Combination With Adoptive T Cell Transfer Eliminates Advanced Tumors Without Off-Target Toxicities in a Melanoma Preclin. Model” <=New(2nd) PPHM+MSK/Wolchok
NON-PEREGRINE:
3. (MSK ONLY): 4-2-17 #874 “Lifting the iron curtain: Imaging cellular barriers to combination chelation-immune checkpoint therapy”
4. (MSK & Genocea Bio. http://www.genocea.com GNCA/$130mm MktCap) 4-2-17 #632 “Genome-scale neoantigen screening using ATLAS™ prioritizes candidate antigens for immunotherapy in a NSCLC patient”
=>5. (MSK & Cedars-Sinai/LA) 4-4-17 #4705 “CTLA4 blockade with HER2-directed therapy yields clinical benefit in women undergoing Rad therapy for HER2+ breast cancer brain metastases” <=Note: Lead Author Heather L. McArthur, Medical Dir./Breast Oncology at Cedars-Sinai MC, lists PPHM in her disclosures.